Table 1 Functional antibody response summary.

From: Impact of adjuvants on the biophysical and functional characteristics of HIV vaccine-elicited antibodies in humans

 

Day 0

Day 182

Day 532

ADCC-GTL(AUC)

 C: Placebo

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

 T1: Alum

1.00 (1.00, 1.00)

8689.60 (1.00, 15595.38)

1.00 (1.00, 1.00)

 T2: Liposomal MPL

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

 T4: MF59

1.00 (1.00, 1.00)

9638.29 (1.00, 41686.94)

1.00 (1.00, 1.00)

 T5: MF59 + MTP-PE

1.00 (1.00, 1.00)

28055.91 (11376.78, 64227.95)

1.00 (1.00, 1026.75)

 T6: SAF/2

1.00 (1.00, 1.00)

184077.20 (50194.54, 277732.64)

9155.15 (1706.60, 42571.92)

 T7: SAF/2 + MDP

1.00 (1.00, 1.00)

49373.10 (1.00, 223094.62)

3507.78 (1.00, 8211.18)

ADCC-LUC (AUC)

 C: Placebo

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

 T1: Alum

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

 T2: Liposomal MPL

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

 T4: MF59

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

1.00 (1.00, 1.00)

 T5: MF59 + MTP-PE

1.00 (1.00, 1.00)

1.00 (1.00, 4802.65)

1.00 (1.00, 1.00)

 T6: SAF/2

1.00 (1.00, 1.00)

5432.50 (1.00, 86271.52)

1.00 (1.00, 29364.92)

 T7: SAF/2 + MDP

1.00 (1.00, 1.00)

5026.30 (221.52, 27427.18)

1.00 (1.00, 6627.65)

ICABA (MFI)

 C: Placebo

0.00 (0.00, 0.00)

0.00 (0.00, 0.00)

0.00 (0.00, 100.25)

 T1: Alum

0.00 (0.00, 0.00)

0.00 (0.00, 165.50)

0.00 (0.00, 217.75)

 T2: Liposomal MPL

0.00 (0.00, 0.00)

0.00 (0.00, 64.25)

0.00 (0.00, 0.00)

 T4: MF59

0.00 (0.00, 0.00)

0.00 (0.00, 0.00)

0.00 (0.00, 0.00)

 T5: MF59 + MTP-PE

0.00 (0.00, 0.00)

229.50 (0.00, 604.50)

0.00 (0.00, 0.00)

 T6: SAF/2

0.00 (0.00, 0.00)

672.00 (124.00, 831.00)

70.00 (0.00, 965.25)

 T7: SAF/2 + MDP

0.00 (0.00, 0.00)

820.00 (482.50, 1409.00)

82.00 (0.00, 596.50)

ADCP Score

 C: Placebo

1.48 (1.06, 2.18)

1.00 (0.75, 1.49)

1.02 (0.80, 1.41)

 T1: Alum

1.55 (1.10, 2.19)

11.45 (8.34, 12.74)

2.30 (1.48, 3.02)

 T2: Liposomal MPL

1.70 (1.15, 2.10)

2.88 (2.06, 3.76)

1.70 (1.50, 2.10)

 T4: MF59

1.45 (1.20, 2.25)

13.75 (11.60, 16.23)

5.03 (2.95, 6.44)

 T5: MF59 + MTP-PE

1.33 (0.95, 2.22)

15.18 (13.61, 16.90)

8.80 (7.66, 12.45)

 T6: SAF/2

1.40 (1.16, 2.05)

13.50 (12.70, 15.85)

11.65 (11.43, 12.38)

 T7: SAF/2 + MDP

1.35 (1.00, 2.54)

15.22 (13.45, 17.96)

10.40 (8.85, 14.35)

Trogocytosis (AUC)

 C: Placebo

12.65 (9.03, 16.94)

3.70 (3.30, 9.88)

 

 T1: Alum

6.36 (2.29, 12.31)

78.64 (55.73, 109.43)

 

 T2: Liposomal MPL

6.14 (1.85, 12.47)

11.69 (10.26, 22.09)

 

 T4: MF59

5.58 (2.17, 12.17)

69.78 (24.48, 119.60)

 

 T5: MF59 + MTP-PE

7.44 (4.08, 11.76)

120.80 (62.02, 195.42)

 

 T6: SAF/2

11.52 (5.16, 21.83)

218.00 (173.55, 277.10)

 

 T7: SAF/2 + MDP

7.37 (3.24, 8.64)

219.20 (206.02, 244.00)

 
  1. Median and interquartile range (25th, 75th percentiles) of functional response values by group at days 0, 182, and 532 (pre-immunization, 2 weeks post final immunization, and 1 year post final immunization, respectively). Trogocytosis was not run on Day 532 due to sample availability. ADCC-GTL and ADCP responses were measured to SF-2 gp120; ADCC-LUC and ICABA responses were measured to an SF162 infectious molecular clone; and trogocytosis responses were measured to BaL gp120.
Back to article page